Research Article

Quantum Chemical Benchmark Study on Valdecoxib, a Potent and Selective Inhibitor of COX-2, and its Hydroxylated Derivative

Volume: 43 Number: 2 June 29, 2022
EN

Quantum Chemical Benchmark Study on Valdecoxib, a Potent and Selective Inhibitor of COX-2, and its Hydroxylated Derivative

Abstract

In this work, quantum chemical calculations were performed on valdecoxib (VLB), a highly selective and potent COX-2 inhibitor, and its hydroxylated derivative (1H-VLB), an active metabolite. The geometry optimizations and frequency calculations were carried out by using density functional theory (DFT)/B3LYP functional with the 6-311++G (d, p) basis set. To define water phase behaviors, calculations were renewed by using universal SMD solvation model for both molecules. Structural and thermodynamic parameters, FT-IR analysis, Mulliken population analysis (MPA), frontier molecular orbital (FMO) analysis, natural bond orbital (NBO) analysis, and electrostatic surface properties were investigated in detail. Quantum chemical reactivity identifiers were calculated separately for both vacuum and water environment in order to evaluate the bioactivity tendency of both mentioned compounds. When the bioactivity of VLB and 1H-VLB molecules were compared based on quantum chemical reactivity identifiers, it was observed that the VLB molecule was more active. Moreover, drug-likeness properties of studied molecules were predicted by means of Molinspiration cheminformatics software. Molecular lipophilicity potential (MLP) maps that exhibit the accumulative lipophilic contributions of each atom in studied molecules were visualized.

Keywords

References

  1. [1] Vane J.R., Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs, Nature New Biol., 231 (1971) 232–235.
  2. [2] Fu J. R., Masferrer J. L., Seibert K., Raz A., Needle-man P., The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes, J. Biol. Chem., 265 (1990) 265 16737-16740.
  3. [3] Battistini B., Botting B., Bakhle Y., SCOX-1 and COX-2:Toward the development of more selective NSAİDs, Drug News Perspect., 7 (1994) 501.
  4. [4] Sayed G., Abou-seri S.M., Kamel G., Moawad M., Celecoxib analogs bearing ben- zofuran moiety as cyclooxygenase-2 inhibitors : design, synthesis and evalua- tion as potential anti-inflammatory agents, Eur. J. Med. Chem., 76 (2014) 482–493.
  5. [5] Abdelall E.K.A., Lamie P.F., Ahmed A.K.M., El-nahass E., COX-1/COX-2 inhibi- tion assays and histopathological study of the new designed anti-inflammatory agent with a pyrazolopyrimidine core, Bioorg. Chem., 86 (2019) 235–253.
  6. [6] Raz A., Wyche A., Siegel N., Needleman P., Regulation of fibroblast cyclooxygenase synthesis by interleukin-1, J. Biol.Chem., 263 (1988) 263 3022-3028.
  7. [7] Wang C., Chen F., Qian P., Cheng J., Recent advances in the Rh-catalyzed cascade arene C–H bond activation/annulation toward diverse heterocyclic compounds, Org. Biomol. Chem., 19 (2021) 1705-1721.
  8. [8] Mermer A., Keleş T., Şirin Y., Recent studies of nitrogen containing heterocyclic compounds as novelantiviral agents: A review, Bioorg. Chem., 114 (2021) 105076.

Details

Primary Language

English

Subjects

-

Journal Section

Research Article

Publication Date

June 29, 2022

Submission Date

March 11, 2022

Acceptance Date

May 27, 2022

Published in Issue

Year 2022 Volume: 43 Number: 2

APA
Serin, S., & Doğan Ulu, Ö. (2022). Quantum Chemical Benchmark Study on Valdecoxib, a Potent and Selective Inhibitor of COX-2, and its Hydroxylated Derivative. Cumhuriyet Science Journal, 43(2), 221-231. https://doi.org/10.17776/csj.1086277

Cited By

As of 2026, Cumhuriyet Science Journal will be published in six issues per year, released in February, April, June, August, October, and December